Loading stock data…
PHIO
$1.08-0.01 (-0.92%)
After Hours$1.07-0.01 (-0.68%)· Last close Jun 9
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phio Pharmaceuticals Corp. in the Healthcare sector is trading at $1.08. Wall Street consensus targets $14.00 (1 analysts), implying a +1196.3% move over the next 12 months. The stock is currently near its 52-week low of $0.81, remaining 24.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1196.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.08
Potential Downside
0%
Whystock Fair Value$1.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$14.00+1196.3%
Range$14.00 – $14.00
Fundamentals
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.41%
Volume
Today's trading volume
175,148
Recent News
BC-Most Active Stocks
CCH Holdings Ltd. 18,962,694 1.32
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
Asian equities traded in the US as American depositary receipts were sharply higher Thursday morning
Phio Reports Tumor Responses in PH-762 Phase 1b Cancer Trial; Shares Surge
Phio Pharmaceuticals (PHIO) said Friday its experimental cancer therapy PH-762 showed a complete pat